Sigma-Aldrich Signs Exclusive Agreement with Rubicon Genomics to Commercialize Transplex™
News Dec 15, 2006
The TransPlex technology is a method which can be used for amplifying total RNA from a variety of sample sources such as animals, plants, and micro-organisms.
Under the terms of the agreement, Rubicon retains all rights to TransPlex™ for molecular diagnostics.
"We are excited to have this opportunity to expand our relationship with Rubicon," said Keith Jolliff, Director of Marketing for Genomics and Functional Genomics.
"Sigma-Aldrich is committed to bringing best-in-class- technologies to the genomic research community, and the TransPlex™ Whole Transcriptome Amplification kit is clearly in that category."
John Langmore, VP of Commercial Development at Rubicon, said: "Rubicon is very pleased that Sigma-Aldrich will be marketing TransPlex kits to complement the very successful GenomePlex® Whole Genome Amplification kits. We have confidence that their customers will embrace TransPlex for biological research and development of diagnostic products."
TransPlex WTA is designed to create a cDNA library from the isolated RNA template and to amplify the library in a single PCR reaction as the TransPlex reagents and protocols are optimized to ensure a linear representation of all expressed genes and exons that allow RNA samples to be amplified 1,000-10,000 fold in less than four hours.
This technology is made to work well even when the RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.